Clinical trial

A Two-part Study of Lembas Edge Evaluating Tolerability and Postprandial Glycemic Control

NCT07711288

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-10-01

PhaseNA

Study timeline

Study start (estimated)2026-10-01Date precision: month

Registry last updated2026-09-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Postprandial Glycemic Controlunresolved

Prediabetic Overweight and Obese Adultsunresolved

Interventions

Low dose alpha-galactosidase-derived peptideDIETARY_SUPPLEMENT

Medium dose alpha-galactosidase-derived peptideDIETARY_SUPPLEMENT

High dose alpha-galactosidase-derived peptideDIETARY_SUPPLEMENT

PlaceboDIETARY_SUPPLEMENT

Sponsors & collaborators

Lembaslead sponsor

KGK Science Inc.collaborator

Mapped research locations

LondonOntario, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07711288 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.